FGF2 and breast cancer: When tested against different angiogenic stimuli (FGF1, FGF2, FGF8, EGF and VEGF) in breast tumor models, PF4 peptides, CXCL4 (47–70) and CXCL4L1 (47–70), exhibited angiostatic, macrophage inflammatory and anti-tumor effects in an EGF-dependent breast cancer model [18].